MET and neoplasm: The main driver mutations of primary tumours with LM were determined by NGS, including EGFR L858R (10, 35.7%), EGFR 19del (6, 21.4%), EGFR L858R + MET amplification (1, 3.6%), EGFR L858R+S768I (1, 3.6%), ALK (2, 7.1%), ROS1 (1, 3.6%), negative (5, 17.9%), and unknown (2, 7.1%) (Figure 2A).